AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...
AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...
Abstract: Asthma and chronic obstructive pulmonary disease (COPD) are common respiratory diseases, and the proper use of inhalers is crucial for effective symptom management. However, many patients ...
Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...
Respiratory inhaler devices are essential tools for delivering medication directly into the lungs for the treatment and management of respiratory conditions such as asthma, chronic obstructive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback